

# Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibody in Patients with Rheumatoid Arthritis

XIAOFENG ZENG, MAIXING AI, XINPING TIAN, XIAODAN GAN, YANPING SHI, QINFANG SONG, and FULIN TANG

**ABSTRACT.** *Objective.* To explore the diagnostic value of anti-cyclic citrullinated peptide antibody (anti-CCP) detected by ELISA in patients with rheumatoid arthritis (RA).

*Methods.* The synthesized cyclic citrullinated peptide was used as substrate for ELISA. Anti-CCP antibody was detected by ELISA in 191 patients with RA, 132 with rheumatic diseases other than RA, and 98 with nonrheumatic diseases. The antiperinuclear factor (APF), anti-keratin antibody (AKA), rheumatoid factor (RF), and HLA-DR4 gene complex were also tested in each RA patient. The results of these tests were compared with anti-CCP antibody to examine the correlation between them.

*Results.* Ninety (47.1%) patients with RA, 4 (3.0%) with other rheumatic diseases, and 2 (2.0%) with nonrheumatic diseases were found to be anti-CCP antibody positive by ELISA. The sensitivity of anti-CCP antibody was 47.1%, with a high specificity (97.4%) in RA. Anti-CCP antibody correlated with APF, AKA, RF, and HLA-DR4 gene complex.

*Conclusion.* A new modified anti-CCP antibody test had a moderate sensitivity (47.1%) but a high specificity (97.4%) in patients with RA and was found as a valuable supplement to diagnosis of RA. Anti-CCP correlated with APF, AKA, RF, and HLA-DR4 gene complex, but did not completely overlap with them. Anti-CCP antibody could be regarded as a new diagnostic marker for RA. (J Rheumatol 2003;30:1451-5)

## Key Indexing Terms:

CYCLIC CITRULLINATED PEPTIDE ANTIBODY  
AUTOANTIBODIES

RHEUMATOID ARTHRITIS  
DIAGNOSTIC ELISA

Rheumatoid arthritis (RA) is a systemic autoimmune disease that can lead to irreversible joint damage even in the first 2 years of disease. The most effective way to manage RA patients is early diagnosis and timely treatment with disease modifying antirheumatic drugs (DMARD), which prevent the exacerbation of disease, reduce the probability of joint destruction, and improve the outcome<sup>1</sup>. The only serologic indicator routinely used in RA diagnosis is the IgM rheumatoid factor (RF), which bears a low specificity because it can be found in a variety of patients with other autoimmune diseases as well as in healthy people, although at a lower frequency<sup>2</sup>.

Two other antibodies, antiperinuclear factor (APF) and

antikeratin antibodies (AKA), associated with antilaggrin antibodies (AFA), have all been shown to be highly specific for RA, and can be detected in early stage RA<sup>3-5</sup>. All these antibodies target epitopes carried by profilaggrin or laggrin molecules<sup>6,7</sup>. Protein maturation follows a common post-translational pathway, which involves peptidyl-arginine to citrulline deimination. Recently, a new serologic test based on the modified amino acid citrulline, anti-cyclic citrullinated peptide (anti-CCP), was developed. According to recent data, anti-CCP had an excellent specificity and a relatively high sensitivity for RA, especially for recent onset RA<sup>8-10</sup>.

We describe a modified ELISA for detecting anti-CCP antibodies in patients with RA.

## MATERIALS AND METHODS

*Serum samples.* We collected serum samples from 191 RA outpatients from the clinic of the Peking Union Medical College Hospital. One hundred thirty-three were female and 58 were male, with a mean age of 47 years (range 15-77). All patients had a diagnosis of definite RA according to the revised criteria of the American College of Rheumatology (ACR)<sup>11</sup>. Sixty of these patients were classified as recent onset RA (symptom duration < 1 year at study entry).

To provide the data for specificity analysis, 230 control sera samples from 132 patients with non-RA rheumatic diseases, 98 patients with nonrheumatic diseases, and 90 healthy individuals were collected and tested (Tables 1 and 2).

*Peptide synthesis and ELISA.* The cyclic peptide (cfc1-cyc) was synthe-

From the Department of Rheumatology, Chinese Academy of Medical Science, Peking Union Medical College Hospital; and Department of Rheumatology, Capital University of Medical Science, Beijing Friendship Hospital, Beijing, China.

X.F. Zeng, MD, Professor of Medicine; F.L. Tang, MD, Professor of Medicine; X.P. Tian, MD, Associate Professor of Medicine; X.D. Gan, BA, Research Associate; Y.P. Shi, Research Assistant; Q.F. Song, Research Associate, Department of Rheumatology, Chinese Academy of Medical Science, Peking Union Medical College Hospital; M.X. Ai, MD, Assistant Professor of Medicine, Department of Rheumatology, Capital University of Medical Science, Beijing Friendship Hospital.

Address reprint requests to Dr. X.F. Zeng, Department of Rheumatology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, Beijing, China.

Submitted May 29, 2002; revision accepted December 19, 2002.

sized by the solid-phase strategy using fmoc chemistry as described<sup>9</sup>. The peptide was at least 95% pure as deduced from its elution pattern on reverse-phase high performance liquid chromatography. The identity of the peptide was confirmed by amino acid sequencing and mass spectrometry.

Anti-CCP antibody was tested by ELISA essentially as described in detail by Schellekens, *et al*<sup>9</sup>. We modified the ELISA as follows. Synthetic peptide was diluted to a concentration of 1 µg/100 µl in 0.01 M phosphate buffered saline (PBS) (pH 7.4) and 96-well MaxiSorp microtitration plates (Nunc, Roskilde, Denmark) were coated by an overnight incubation at 4°C with the solutions. After blocking with 2% bovine serum albumin (BSA) in 0.01 M PBS (pH 7.4) at 37°C for 2 h, sera were diluted 100-fold in 2% BSA and incubated at 37°C for 1.5 h. After washing with 0.05% PBST [PBS/0.05% (v/v) Tween-20, 3 times], 100 µl anti-human IgG (Fab-specific, developed in goat) conjugated to peroxidase (Sigma Chemical, Rehovot, Israel) with a dilution of 1:1000 in 2% BSA was added to the well and incubated at 37°C for 1 h. The wells were then washed 3 times, and reacted for 20 min with 3,3',5,5'-tetramethylbenzidine (Sigma Chemical, St. Louis, MO, USA). Color development was stopped with 2 M H<sub>2</sub>SO<sub>4</sub>. The result was read at 450 nm by a micro-ELISA reader (Model 550, Bio-Rad Laboratories, Hercules, CA, USA). All samples were tested twice and results were averaged.

To evaluate the repeatability and reproducibility of the test, 9 RA samples with 3 negative (< 99 units), 3 intermediate (about 500 units), and 3 high (> 1000 units) antibody concentrations and all 7 sera samples from non-RA subjects (6 non-RA, one healthy subject) with positive reactions were assessed 6 times by 3 independent groups of operators under identical experimental conditions on different days. The intra- and inter-test variations were less than 5% at all times.

Table 1. Characteristics of the study patients.

	RA	RD	Non-RD
No. of patients	191	132	98
Age, yrs, mean (range)	47 (15–77)	45 (16–72)	46 (16–75)
Female, %	69.6	77.3	68.4

RD: rheumatic disease other than RA; Non-RD: Nonrheumatic disease.

**Detection of APF, AKA, RF, and HLA-DR4 gene complex.** APF and AKA were detected by indirect immunofluorescence (IIF). Buccal mucosa cells were used for the APF test and cornified layer of rat esophagus cryostat sections were used for AKA detection. All the slides were read independently by 2 observers. IgM RF was measured by nephelometry, and a level > 20 IU/ml was considered positive. HLA-DR4 gene complex was detected by polymerase chain reaction<sup>12</sup>.

**Statistical analysis.** Statistical analysis was performed using SPSS 10.0 software. The chi-square test was used for testing the significance of differences between 2 different groups of patients. Multiple regression analyses were used to assess the importance of the different variables relative to anti-CCP antibody status. Means, standard deviations, and confidence intervals (CI) were used where appropriate. Two-sided *p* < 0.05 was considered significant. Receiver operating characteristics (ROC) were used to calculate optimal cutoff values<sup>13</sup>.

## RESULTS

**Sensitivity and specificity of anti-CCP antibody.** Ninety of 191 (47.1%) RA patients were positive for anti-CCP antibody. Only 6 of 230 (2.6%) control sera (including 132 serum samples from other rheumatic diseases and 98 serum samples from nonrheumatic diseases) had a positive reaction (Table 2), including one patient with primary Sjögren's syndrome complicated with renal tubular acidosis, 2 with systemic sclerosis who had distal digital ulcer and bone erosion, one vasculitis, one tuberculosis, and one with viral infection. Only one of 90 healthy controls was positive for anti-CCP antibody. None of these 7 anti-CCP positive controls had symptoms or signs of RA. At a cutoff value of 99 units determined by ROC curve (Figure 1), the sensitivity of anti-CCP antibody was 47.1% (CI 40.0–54.2%) with a specificity of 97.4% (CI 95.3–99.5%). The positive predictive value and negative predictive values were 93.8% and 68.9%, respectively.

Of the 60 patients with early RA (symptom duration < 1 year at study entry), 26 were anti-CCP antibody positive and

Table 2. Results of anti-CCP antibody in RA patients and controls.

Patient Group	Total, n	Anti-CCP positive sera, No. (%)
Rheumatoid arthritis	191	90 (47.1)
Early RA	60	26 (43.3)
Other rheumatic diseases	132	4 (3.0)
Systemic lupus erythematosus	15	0
Systemic sclerosis	20	2
Primary Sjögren's syndrome	15	1
Osteoarthritis	20	0
Ankylosing spondylitis	20	0
Reactive arthritis	15	0
Polymyositis/dermatomyositis	10	0
Vasculitis	17	1
Nonrheumatic diseases	98	2 (2.0)
Tuberculosis	20	1
Infectious endocarditis	10	0
Virus infections	30	1
Ulcerative colitis	18	0
Crohn's disease	10	0
Autoimmune hepatitis	10	0
Healthy individuals	90	1 (1.1)




Figure 1. Receiver operating characteristics curve of anti-cyclic citrullinated peptide antibody (anti-CCP). ■ marks the optimal cutoff value for the anti-CCP ELISA (99 units). Area under the curve (AUC) was 0.764. The patients shown in Table 2 were included in this evaluation.

the sensitivity was 43.3%. There was no association between anti-CCP antibody and age or sex.

The repeatability and reproducibility of the assay we set up were reliable and the intra- and inter-test variations of the identical sample were less than 5% at all times.

**Correlation among anti-CCP antibody, APF, and AKA.** We also performed APF and AKA by IIF in 191 RA patients. Of the 191 sera samples, 61 were positive for anti-CCP antibody, APF, or AKA, and 83 were negative for all; 69 were positive for anti-CCP antibody or APF and 84 were negative for both; and 63 were positive for anti-CCP antibody or AKA and 89 were negative for both. The sensitivity of anti-CCP antibody was higher than for APF and AKA, and the difference between anti-CCP antibody and AKA was statistically significant ( $p = 0.025$ ). The correlation of results of anti-CCP antibody, APF, and AKA was statistically significant ( $p < 0.01$ ) (Table 3).

Table 3. Test results of anti-CCP antibody in relation to APF and AKA positive or negative in patients with RA.

Group	Anti-CCP(n)		Total (n)
	+	–	
APF +/AKA +	61	11	72
APF +/AKA –	8	6	14
APF –/AKA +	2	1	3
APF –/AKA –	19	83	102
Total (n)	90	101	191

APF: antiperinuclear factor; AKA: anti-keratin antibody.

**Correlation among anti-CCP, RF, and HLA-DR4 gene complex.** We also tested RF in 191 sera samples from patients with recent onset RA. Of the 191 samples, 72 were positive for anti-CCP or RF and 60 were negative for both; 18 were positive for anti-CCP antibody or negative for RF and 41 were negative for anti-CCP antibody or positive for RF. The correlation of anti-CCP and RF was statistically significant ( $p < 0.001$ ). We also investigated HLA-DR4 gene complex occurrence in the same series of samples of RA patients: HLA-DR4 gene complex was positive in 108 sera (56.5%) and negative in 83 sera. The correlation of results between anti-CCP antibody and HLA-DR4 gene complex was statistically significant ( $p < 0.01$ ).

## DISCUSSION

The critical strategy to prevent joint damage in RA treatment is to initiate DMARD therapy early in the disease course. RA is diagnosed primarily according to clinical manifestations and serologic test that is limited to the presence of IgM RF. RF is highly sensitive for RA patients, but has a low specificity, as it can be found in a variety of conditions such as other nonrheumatic autoimmune diseases and infectious diseases, and even in healthy elderly individuals.

APF and AKA are not popular because of problems with antigen preparation and test methods. Although the AFA could be detected by Western blot and ELISA and showed a high specificity, the sensitivity of the AFA varied from 12% to 54%, depending on the method for purification of filaggrin<sup>14,15</sup>. APF, AKA, and AFA are all present in the early stage of the disease<sup>4-7,14,15</sup>. Recently, several studies have shown that antibodies specific for RA bound to antigenic determinants that contained citrulline residues, including filaggrin and Sa system<sup>16-18</sup>, but CCP was the most specific one for RA, and could be detected early in the disease course. Schellekens, *et al* synthesized a modified peptide variant, a single cyclic peptide with a mimic  $\beta$ -turn conformation, named cyclic citrullinated peptide (CCP)<sup>8,9</sup>. CCP was recognized by RA autoantibodies with relatively high sensitivity in a reliable and convenient test format.

We evaluated the diagnostic accuracy of a modified ELISA for anti-CCP antibody in Chinese patients. In the 191 RA subjects studied, the diagnostic sensitivity of the test was 47.1% and the specificity was as high as 97.4%. Our result confirmed those obtained initially by other authors<sup>9,10,16,19,20</sup>. Table 4 shows the prevalence differences of anti-CCP antibody in RA patients in the literature, which ranged from 68% to 41%. Our result of 47% was within the range of prevalence. In our assay, we compared the Costar assay plates, used in the work of Schellekens and Kroon<sup>8,10</sup>, to Nunc assay plates, and radioimmunoassay buffer [1% BSA, 0.35 M NaCl, 0.01 M Tris HCl buffer, pH 7.6, 1% (v/v) Triton X-100, 0.5% (w/v) Na-deoxycholate, 0.1% sodium dodecyl sulfate] supplemented with 10% normal rabbit serum to our working diluting buffer (2% BSA). The

Table 4. Percentage of serum samples positive for anti-CCP antibody in patients with RA and controls — summary of published reports.

First Author, year <sup>ref</sup>	RA* Samples		Control Samples	
	No.	Anti-CCP+, %	No.	Anti-CCP+, %
Schellekens, 2000 <sup>9</sup>	134	68	815	2
Kroot, 2000 <sup>10</sup>	273	66	NA	NA
Goldbach-Mansky, 2000 <sup>16</sup>	106	41	132	9
Bizzaro, 2001 <sup>19</sup>	98	41	232	3
Our results, this article	191	47	320	2

NA: Not available. CCP: Cyclic citrullinated peptide antibody.

difference between the results was not statistically significant (results not shown). So, the various geographical areas were considered as the primary factor affecting prevalence of anti-CCP antibody. In our cohort, the sensitivity of RF in RA patients was higher than that of anti-CCP antibody (59% vs 47%), but was lower than the average sensitivity (about 60%–80%) outside China. Further research is required to illustrate the differences including geographical factors between our results and others’.

Our data clearly indicate that reactivity to CCP did not capture the complete spectrum of APF and AKA reactivity. A potential explanation for this might relate to the demonstration that citrulline has been shown to be an essential constituent of the antigenic determinants recognized by APF and AKA, but individual RA patients responded to different antigenic determinants.

Anti-CCP positivity correlated with RF positivity. Combining RF with anti-CCP antibody could provide a much higher sensitivity without compromising specificity for the diagnosis of RA. There was a direct correlation between anti-CCP and HLA-DR4 gene complex, in agreement with the fact that both assays predicted more progressive disease course<sup>9,10,21,22</sup>.

In conclusion, anti-CCP antibody detection by an easy-to-use ELISA avoided many of the problems of the APF and AKA tests regarding quantification of results and standardization of the assay. The anti-CCP antibody response has been shown to be very specific for RA, to be able to diagnose RA at a very early stage of the disease, and to predict a more destructive disease course<sup>10,22,23</sup>. Moreover, when combined with the APF or AKA and RF, it provided high specificity and thus could be very helpful in the differential diagnosis of RA. Anti-CCP has the potential to become another serologic marker for RA.

## ACKNOWLEDGMENT

We are grateful to Dr. M. van Boekel, University of Nijmegen, The Netherlands, for the standard anti-CCP positive sera.

## REFERENCES

1. Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. *Bull Rheum Dis* 1998;47:2-7.
2. Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assay in rheumatoid arthritis. *Ann Rheum Dis* 1996;55:157-61.
3. Nienhuis RLF, Mandema EA. A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. *Ann Rheum Dis* 1964;23:302-3.
4. Young BJJ, Mallya RK, Leslie RDG, Clark CJM, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. *BMJ* 1979;2:97-9.
5. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific auto-antibodies. *J Clin Invest* 1995;95:2672-9.
6. Hoet RM, Boerbooms AM, Arends M, Ruiter DJ, van Venrooij WJ. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. *Ann Rheum Dis* 1991;50:611-8.
7. Simon M, Girbal E, Sebbag M, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. *J Clin Invest* 1993;92:1387-93.
8. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. *J Clin Invest* 1998;101:273-81.
9. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. *Arthritis Rheum* 2000;43:155-63.
10. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. *Arthritis Rheum* 2000;43:1831-5.
11. Arnett FC, Edworthy SM, Bloch DA, et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
12. Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. *Proc Natl Acad Sci USA* 1989;86:10049-53.
13. Zweig MH, Campbell G. Receiver-operating characteristics (ROC) plots: a fundamental valuation tool in clinical medicine. *Clin Chem* 1992;39:561-77.
14. Slack SL, Mannik M, Dale BA. Diagnostic value of antibodies to filaggrin in rheumatoid arthritis. *J Rheumatol* 1998;25:847-51.
15. Palosuo T, Lukka M, Alenius H, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. *Int Arch Allergy Immunol* 1998; 115:294-302.
16. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis

- associated autoantibodies in patients with synovitis of recent onset. *Arthritis Res* 2000;2:236-43.
17. Menard HA, Lapointe E, Rochdi MD, et al. Insights into rheumatoid arthritis derived from the Sa immune system. *Arthritis Res* 2000;2:429-32.
  18. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. *J Immunol* 1999;162:585-94.
  19. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. *Clin Chem* 2001;47:1089-93.
  20. van Jaarsveld CH, ter Borg EJ, Jacobs JW, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. *Clin Exp Rheumatol* 1999;17:689-97.
  21. van Zeben D, Hazes JM, Zwinderman AH, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. *Arthritis Rheum* 1991;34:822-30.
  22. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. *Arthritis Rheum* 2002;46:357-65.
  23. van Boekel MAM, Vossenaar ER, van den Hoogen FHJ. Auto-antibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. *Arthritis Res* 2002;4:87-93.